US biotech Bluebird Bio said it would sell its gene replacement therapy through a 2020 instalment plan to tackle the expected $1m or more price of the treatment, designed for a rare inherited blood disease. CEO Nick Leschly said the total price end up considerably less than the $2.1m it said the treatment was intrinsically worth. The treatment for beta thalassemia, which affected 300,000 people globally and 1,000 in the US, could be cleared for sale by five-year. The plan meant Bluebird would receive 20% of the treatment’s value upfront, with subsequent payments-based effectiveness.
US biotech Bluebird Bio said it would sell its gene replacement therapy through a five-year instalment plan to tackle the expected $1m or more price of the treatment, designed for a rare inherited blood disease. CEO Nick Leschly said the total price end up considerably less than the $2.1m it said the treatment was intrinsically worth. The treatment for beta thalassemia, which affected 300,000 people globally and 1,000 in the US, could be cleared for sale by 2020. The plan meant Bluebird would receive 20% of the treatment’s value upfront, with subsequent payments-based effectiveness.